- RecruitingPHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This study looks at new combinations of medicines for men with prostate cancer that has spread. It checks if combining a new drug, tulmimetostat, with existing treatments like darolutamide or abiraterone is safe and works well. The goal is to find better ways to treat this type of cancer.
For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)United States · Australia · Brazil - Active not recruitingPHASE3
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
This study is testing a new drug, Saruparib, for men with advanced prostate cancer that is still responding to hormone treatment. It aims to see if adding Saruparib to standard hormone therapy works better than standard therapy alone to slow down cancer growth.
For: Metastatic Castration-Sensitive Prostate CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
TT-702 in Patients With Advanced Solid Tumours.
This study is testing a new drug, TT-702, for people with advanced cancers. We want to find a safe dose of TT-702, by itself and with another drug called darolutamide, and see how it affects tumours.
For: Advanced Solid TumorsUnited Kingdom - RecruitingPHASE1, PHASE2
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug combination, Gedatolisib and Darolutamide, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. It helps work out the best dose and how well it works.
For: mCRPC (Metastatic Castration-resistant Prostate Cancer) · Genital Diseases, Male · Urogenital Diseases, MaleUnited States · France · Spain - RecruitingPHASE1
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
This study looks at new treatments, Saruparib and Darolutamide, for men recently diagnosed with prostate cancer before surgery. Researchers want to understand how these drugs affect the cancer, either alone or when used together.
For: Prostate CancerUnited States · Australia · Canada - Active not recruitingPHASE3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This study looks at new ways to treat prostate cancer that hasn't spread but is at medium risk of doing so. It uses a gene test to decide if less or more intense treatment might be better, hoping to reduce side effects or improve outcomes.
For: Prostate AdenocarcinomaUnited States · Canada - Not yet recruitingPHASE2
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
This study looks at treating intermediate-risk prostate cancer with radiation and a new hormone therapy. It aims to see if adding the hormone therapy package (darolutamide + degarelix) works better than radiation alone, especially for certain men.
For: Prostate CancerCanada - RecruitingPHASE3
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
This study is testing new ways to treat prostate cancer that is considered high-risk. It combines a new drug called darolutamide and a special type of radiation therapy with standard treatments to see if they can better stop the cancer from spreading.
For: High Risk Prostate Carcinoma · Prostate CancerFrance · Martinique - Active not recruitingPHASE1, PHASE2
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
This study is looking at a new drug, AZD5305, combined with existing hormone therapies for men with prostate cancer that has spread. It aims to see if the combination is safe, how the body handles it, and if it helps treat the cancer.
For: Metastatic Prostate CancerUnited States · Australia · Italy - Active not recruitingPHASE3
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
This study looks at a new drug called darolutamide, along with standard treatments like radiotherapy and hormone therapy, for men with prostate cancer that's at a very high risk of coming back. The aim is to see if this combination can better stop the cancer from spreading and improve their long-term health.
For: Prostate CancerUnited States · Australia · Canada